Fed. Circ. Upholds Patent On Novartis MS Drug
The Federal Circuit on Friday affirmed a lower court's decision that upheld a patent on Novartis AG's multiple sclerosis drug Gilenya, a ruling that will prevent regulatory approval of Ezra Ventures...To view the full article, register now.
Already a subscriber? Click here to view full article